Here are four things to know about the transaction and the company’s stock:
• The shares were sold at an average price of $16.46, for a total value of $196,828.
• Following the transaction, Mr. Pierce now directly owns 28,161 shares of the company’s stock, valued at approximately $463,530.
• The company has an average rating of “buy” and an average target price of $15.63.
• Boston Scientific has a 52-week low of $11.10 and a 52-week high of $16.71.
More articles on GI/endoscopy:
APIC, SHEA address infections linked to duodenscopes
Wisconsin Economic Development Corp. grants Exact Sciences $9M incentive to create 750 jobs
Capsule endoscopy company Check-Cap closes IPO, simultaneous private placement
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.